Omnicell (OMCL) Tops Q2 EPS by 15c; Issues Solid Outlook

Omnicell (NASDAQ: OMCL) reported Q2 EPS of $0.97, $0.15 better than the analyst estimate of $0.82. Revenue for the quarter came in at $273 million versus the consensus estimate of $268.51 million.

“We achieved record revenue, record non-GAAP net income per diluted share, and record non-GAAP EBITDA in the second quarter, as we continue to focus on improving patient health outcomes and support our healthcare systems partners on their journey to the Autonomous Pharmacy,” said Randall Lipps, Chairman, President, Chief Executive Officer, and founder of Omnicell. “Our strong performance in the quarter and year-to-date reflects ongoing robust demand for our solutions and services as hospitals, healthcare systems, and retail pharmacies advance their efforts to optimize and automate medication management and adherence systems. In addition, our Advanced Services portfolio continues to gain momentum in the market. Earlier this week, we announced our intent to acquire FDS Amplicare, a leading provider of pharmacy SaaS solutions that we believe will further strengthen our Advanced Services portfolio, enhancing our ability to deliver best-in-class solutions, and expanding our EnlivenHealth platform. We are excited about the opportunities ahead and believe we are well-positioned to continue to deliver value for our stakeholders.”

GUIDANCE:

Omnicell sees Q3 2021 EPS of $0.89-$0.94, versus the consensus of $0.92. Omnicell sees Q3 2021 revenue of $281-286 million, versus the consensus of $278.67 million.

Omnicell sees FY2021 EPS of $3.65-$3.75, versus the consensus of $3.59. Omnicell sees FY2021 revenue of $1.11-1.15 billion, versus the consensus of $1.1 billion.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance